Key result
The abstract provides only author affiliations and conflict of interest disclosures regarding therapy with inhaled treprostinil, macitentan, and tadalafil/riociguat in pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Karim El‐Kersh (2022) studied High-Risk Pulmonary Arterial Hypertension. Inhaled Treprostinil, Macitentan, and Tadalafil/Riociguat was evaluated. The abstract provides only author affiliations and conflict of interest disclosures regarding therapy with inhaled treprostinil, macitentan, and tadalafil/riociguat in pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: